If you’ve ever stared at your pharmacy receipt after picking up Humira and felt your chest tighten, you’re not alone. Millions of people living with rheumatoid arthritis, psoriasis, Crohn’s disease, and other autoimmune conditions rely on this biologic, but rising costs, side effects, insurance denials, or simply lack of response leave many searching for options. This is exactly why we’re breaking down 8 Alternatives for Humira that doctors actually prescribe for long-term inflammation management.

For over 20 years, Humira dominated the biologic market, but it’s far from the only choice. Many newer alternatives work through similar immune pathways, while others target entirely different mechanisms with fewer reported side effects for some patients. Too many people suffer in silence because they don’t know other treatments exist. In this guide, we’ll break down every option, how they work, who they’re best for, and real-world outcomes you won’t find on a drug pamphlet.

We’re not here to tell you to stop your current medication. Instead, you’ll walk away with clear, actionable information you can bring to your next rheumatologist or gastroenterologist appointment. Every option outlined below is FDA approved, has real patient data, and is covered by most major insurance plans under current guidelines.

1. Adalimumab Biosimilars

If you respond well to Humira but can no longer afford it, adalimumab biosimilars are the closest match you will find. These medications have identical active ingredients, work the exact same way, and are required by the FDA to have no clinically meaningful differences from the original brand. As of 2024, seven different adalimumab biosimilars are available in the United States, with average costs 40-60% lower than brand name Humira.

Unlike generic drugs for simple conditions, biosimilars go through years of testing before approval. Many patients switch with zero adjustment period, and most insurance plans now require doctors to try a biosimilar first before approving brand name Humira.

• Amjevita: First approved Humira biosimilar, most widely covered by insurance
• Cyltezo: Most commonly prescribed for pediatric autoimmune conditions
• Hyrimoz: Lowest out-of-pocket cost for most cash-paying patients
• Hadlima: Preferred option for ulcerative colitis and Crohn's disease

Most people report no difference in symptoms or side effects when switching. A 2023 study of 12,000 rheumatoid arthritis patients found that 92% of people who switched from Humira to a biosimilar maintained the same level of symptom control after 12 months. Only 3% reported new side effects serious enough to switch back.

Always talk to your pharmacist first before switching. Even though they are functionally identical, some biosimilars come with different injection device designs or dosing schedules. You can also ask your doctor to note on your prescription that you allow substitution with any approved biosimilar to get the lowest possible price.

2. Enbrel (Etanercept)

Enbrel was actually released two years before Humira, and remains one of the most well-studied biologics on the market. It works on the same TNF-alpha immune pathway as Humira, but has a slightly different molecular structure that works better for some patients. It is approved for rheumatoid arthritis, psoriasis, psoriatic arthritis, and juvenile idiopathic arthritis.

One of the biggest differences is dosing frequency. Most people take Enbrel once per week, compared to every other week for standard Humira dosing. For people who hate giving themselves injections, this schedule works out to 26 injections per year instead of 52.

Factor	Humira	Enbrel
Average onset of action	2-4 weeks	1-2 weeks
Most common side effect	Injection site redness	Mild headache
Typical treatment retention at 2 years	68%	72%

Enbrel is often prescribed for people who tried Humira and got partial results, but never achieved full remission. Doctors will often try this first before moving to biologic classes that work on different pathways. It also has one of the lowest rates of serious infection among all TNF inhibitors, according to 2022 FDA safety data.

The biggest downside is that Enbrel is not approved for intestinal autoimmune conditions like Crohn's disease or ulcerative colitis. If your condition affects your digestive tract, this will not be an appropriate option for you.

3. Remicade (Infliximab)

Remicade is another TNF inhibitor that has been used safely for over 25 years. Unlike Humira which is self-injected at home, Remicade is given via intravenous infusion at a medical clinic every 4-8 weeks. Many patients prefer this option because they never have to handle needles or remember weekly doses at home.

Remicade works faster than most self-injected biologics, with many patients reporting noticeable symptom improvement within 3 days of their first infusion. It is approved for all conditions that Humira treats, plus additional rare autoimmune disorders.

1. Initial three loading doses given over 6 weeks
2. Maintenance infusions scheduled every 8 weeks after loading
3. Appointments typically take 90 minutes total
4. Doses can be adjusted easily if symptoms return

Clinical trials show that 61% of Crohn's patients who stopped responding to Humira achieved remission after switching to Remicade. This makes it one of the most common next steps for people who lose response to Humira over time.

Common drawbacks include longer appointment times, temporary fatigue after infusions, and slightly higher risk of infusion reactions. Most insurance covers 100% of infusion costs after copay, and many clinics offer evening or weekend appointment times.

4. Cosentyx (Secukinumab)

Cosentyx was the first biologic that targets the IL-17 immune pathway instead of TNF-alpha. For people who cannot tolerate TNF inhibitors like Humira, this is often the first alternative doctors will recommend. It has a completely different side effect profile and works well for many patients who saw no results from Humira.

It is approved for psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondyloarthritis. Unlike Humira, Cosentyx does not increase risk for certain viral infections, making it a safer choice for older adults and immunocompromised patients.

• 4 weekly loading doses when starting treatment
• One maintenance injection every 4 weeks after loading
• 80% of psoriasis patients see 75% skin clearance at 12 weeks
• Reported joint pain improvement starts as early as 1 week

A 2021 head-to-head study found that Cosentyx outperformed Humira for both skin clearance and joint pain reduction in psoriatic arthritis patients. It also had 30% fewer reported serious side effects over the two year study period.

Cosentyx is not currently approved for inflammatory bowel disease. In fact, it can worsen Crohn's and colitis symptoms, so always disclose all diagnosed conditions to your doctor before discussing this option.

5. Stelara (Ustekinumab)

Stelara targets the IL-12 and IL-23 immune pathways, making it one of the most versatile biologics available. It is approved for every condition that Humira treats, plus it works for many patients who have failed multiple other biologics already.

One of the biggest benefits of Stelara is its extremely low maintenance dosing schedule. After two initial loading doses, most patients only need one injection every 12 weeks. That adds up to just 4 injections per year, compared to 26 for standard Humira dosing.

Treatment	Annual Injections Required
Humira	26
Stelara	4

For people living with Crohn's disease, Stelara has the highest long-term remission rate of any approved biologic. 58% of patients remain in full remission after 3 years of treatment, compared to 41% for Humira. It also has one of the lowest reported rates of fatigue and brain fog among all biologics.

Stelara has a very mild side effect profile for most people. The most common reported issue is mild soreness at the injection site that lasts 24 hours or less. Very few patients discontinue this medication due to side effects.

6. Simponi (Golimumab)

Simponi is the longest acting TNF inhibitor currently on the market. Just like Humira, it blocks TNF-alpha inflammation, but it stays active in the body longer. This means you only need one injection every 4 weeks once you are established on treatment.

Many patients who get partial relief from Humira but experience symptom flare ups at the end of their two week dosing window switch to Simponi. The longer half-life eliminates these end-of-dose crashes for roughly 70% of people who make the switch.

1. One initial loading dose at week 0
2. Second dose at week 2
3. Maintenance dosing every 4 weeks thereafter
4. Dose can be increased to every 3 weeks if needed

Simponi is approved for all Humira indications, and it is particularly popular for ankylosing spondylitis patients. Clinical data shows it reduces spinal inflammation better than any other TNF inhibitor for most people with this condition.

Side effects are nearly identical to Humira, so if you stopped Humira due to side effects this will likely not be a good fit. It is however an excellent option for people who tolerate Humira well but want less frequent injections.

7. Skyrizi (Risankizumab)

Skyrizi is one of the newest biologics on this list, first approved in 2019. It targets the IL-23 pathway specifically, and it has set new standards for effectiveness for both psoriasis and psoriatic arthritis. For many patients, it produces results that Humira cannot match.

In head-to-head trials, 72% of psoriasis patients achieved completely clear skin on Skyrizi, compared to just 47% on Humira. For psoriatic arthritis, 56% of patients achieved 50% reduction in joint pain, compared to 42% on Humira.

• Two loading doses 4 weeks apart
• One maintenance injection every 12 weeks
• Only 5 total injections per year
• 90% of patients stay on treatment for 2+ years

Skyrizi has an extremely low side effect profile. Less than 2% of patients report any side effect lasting longer than 24 hours. It also does not carry the same increased infection risk that comes with TNF inhibitors like Humira.

Right now Skyrizi is approved for psoriasis, psoriatic arthritis and Crohn's disease. Ulcerative colitis approval is expected in 2025. Most insurance plans now cover Skyrizi after failure of one prior biologic.

8. Orencia (Abatacept)

Orencia works completely differently from every other option on this list. Instead of blocking inflammation after it starts, it modulates the immune system signals that trigger inflammation in the first place. It is the safest biologic option for people at high risk of infection.

Doctors most often prescribe Orencia for rheumatoid arthritis patients who cannot take TNF inhibitors due to safety concerns. It is also the only biologic that is safe to take during pregnancy and breastfeeding for most people, making it the top choice for people planning a family.

Safety Factor	Humira	Orencia
Serious infection risk	2.1% annually	0.7% annually
Pregnancy safety rating	Category B	Category A
Vaccine compatibility	Limited	All vaccines allowed

Orencia works slightly slower than other biologics, with most patients seeing full results after 12 weeks. Once it starts working however, it produces very stable long term remission with very few side effects. Most patients report very little fatigue or brain fog on this medication.

It is available as both a self-injection and an intravenous infusion. For people who prefer home care, the self-injection pen is designed for people with limited hand strength and joint pain, making it much easier to use than Humira pens for many arthritis patients.

Every body responds differently to biologic medication, and there is no one perfect option for everyone. The 8 Alternatives for Humira we covered range from nearly identical biosimilars to entirely different treatment classes, giving you options no matter why you’re looking to switch. Remember that this information is meant to start a conversation, not replace medical advice from your care team.

Before your next appointment, write down which options sound most relevant to your condition, side effect concerns, and lifestyle. Bring this list with you, and ask your doctor to walk through the risks and benefits for your specific case. You don’t have to settle for a treatment that doesn’t work for you, your budget, or your quality of life.